Aspire Biopharma Holdings (ASBP) Cash from Operations Growth (3y) (2024 - 2026)

Aspire Biopharma Holdings (ASBP) Cash from Operations Growth (3y) (2024 - 2026) Analysis & Trends

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Ops. Growth (3y) (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-0.27%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-7.35%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	16.85%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	52.90%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	96.08%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-24.76%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	10.23%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	6.22%
10	Aspire Biopharma Holdings	8.30 Mn	-3.86 Mn	-30,086.00	-123.32%

Download Data